WallStreetZenWallStreetZen

NASDAQ: RYTM
Rhythm Pharmaceuticals Inc Stock

$42.53+0.66 (+1.58%)
Updated Jun 24, 2024
RYTM Price
$42.53
Fair Value Price
-$25.99
Market Cap
$2.59B
52 Week Low
$15.50
52 Week High
$52.57
P/E
-9.19x
P/B
42.11x
P/S
28.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$91.93M
Earnings
-$273.87M
Gross Margin
88.4%
Operating Margin
-279.84%
Profit Margin
-297.9%
Debt to Equity
3.2
Operating Cash Flow
-$140M
Beta
1
Next Earnings
Jul 30, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RYTM Overview

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RYTM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RYTM ($42.53) is overvalued by 263.66% relative to our estimate of its Fair Value price of -$25.99 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RYTM ($42.53) is not significantly undervalued (263.66%) relative to our estimate of its Fair Value price of -$25.99 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RYTM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RYTM due diligence checks available for Premium users.

Be the first to know about important RYTM news, forecast changes, insider trades & much more!

RYTM News

Valuation

RYTM fair value

Fair Value of RYTM stock based on Discounted Cash Flow (DCF)
Price
$42.53
Fair Value
-$25.99
Undervalued by
263.66%
RYTM ($42.53) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RYTM ($42.53) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RYTM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RYTM price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-9.19x
Industry
-6.96x
Market
30.03x

RYTM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
42.11x
Industry
6.29x
RYTM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RYTM's financial health

Profit margin

Revenue
$26.0M
Net Income
-$141.4M
Profit Margin
-544.4%
RYTM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RYTM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$258.7M
Liabilities
$197.1M
Debt to equity
3.2
RYTM's short-term assets ($235.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RYTM's short-term assets ($235.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RYTM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RYTM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$40.7M
Investing
$30.1M
Financing
$4.2M
RYTM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RYTM vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
RYTM$2.59B+1.58%-9.19x42.11x
AGIO$2.57B+0.02%-7.16x3.45x
ACAD$2.62B+3.79%-1,588.00x5.65x
ADMA$2.55B+0.09%-550.50x16.60x
SWTX$2.67B-0.17%-7.00x4.71x

Rhythm Pharmaceuticals Stock FAQ

What is Rhythm Pharmaceuticals's quote symbol?

(NASDAQ: RYTM) Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol RYTM. Rhythm Pharmaceuticals stock quotes can also be displayed as NASDAQ: RYTM.

If you're new to stock investing, here's how to buy Rhythm Pharmaceuticals stock.

What is the 52 week high and low for Rhythm Pharmaceuticals (NASDAQ: RYTM)?

(NASDAQ: RYTM) Rhythm Pharmaceuticals's 52-week high was $52.57, and its 52-week low was $15.50. It is currently -19.1% from its 52-week high and 174.39% from its 52-week low.

How much is Rhythm Pharmaceuticals stock worth today?

(NASDAQ: RYTM) Rhythm Pharmaceuticals currently has 60,972,909 outstanding shares. With Rhythm Pharmaceuticals stock trading at $42.53 per share, the total value of Rhythm Pharmaceuticals stock (market capitalization) is $2.59B.

Rhythm Pharmaceuticals stock was originally listed at a price of $30.00 in Oct 5, 2017. If you had invested in Rhythm Pharmaceuticals stock at $30.00, your return over the last 6 years would have been 41.77%, for an annualized return of 5.99% (not including any dividends or dividend reinvestments).

How much is Rhythm Pharmaceuticals's stock price per share?

(NASDAQ: RYTM) Rhythm Pharmaceuticals stock price per share is $42.53 today (as of Jun 24, 2024).

What is Rhythm Pharmaceuticals's Market Cap?

(NASDAQ: RYTM) Rhythm Pharmaceuticals's market cap is $2.59B, as of Jun 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Rhythm Pharmaceuticals's market cap is calculated by multiplying RYTM's current stock price of $42.53 by RYTM's total outstanding shares of 60,972,909.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.